Rapid and simple enzyme immunoassays (ElAs) were recently developed to measure 2-hydroxyestrone and 16a-hydroxyestrone in unextracted urine. The balance between these competing estrogen metabolism pathways may serve as a biomarker of breast cancer risk. Before testing these assays in epidemiologic studies, we evaluated their reproducibility, and validity relative to gas chromatography-mass spectroscopy (GC-MS). Overnight 12-hr urine collections from five midfollicular premenopausal women, five midluteal premenopausal women, and five postmenopausal women were aliquoted and stored at -700C. Two aliquots from each woman were assayed with the ElAs in a random, blinded order, monthly over 4 months and 1 year later. Reproducibility over 4 months was good for both metabolites in premenopausal women (coefficient of variation = 8-14%) and satisfactory in postmenopausal women (-19%). Reproducibility over 12 months remained good in premenopausal women, but was poor in postmenopausal women, with mean readings increasing 50 to 100%. Wide variation in estrogen metabolite levels enabled a single EIA measurement to characterize individual differences among premenopausal women in midfollicular (intraclass correlation coefficient = 98-99%) and midluteal phase (85-91%). A narrower range in metabolite levels among postmenopausal women reduced discrimination (78-82%). The correlation between EIA and GC-MS measurement was excellent for both metabolites (r>0.9), except for 2-hydroxyestrone in postmenopausal women (r= 0.6). Analysis of absolute agreement suggested that both ElAs were less sensitive than GC-MS, and each detected nonspecific background.
Introduction
Experimental, epidemiologic, and clinical evidence strongly suggests that endogenous estrogens influence breast carcinogenesis although the active form(s) of estrogen and the specific mechanisms remain unclear (1) . In 1982, the relative importance of two major, mutually exclusive pathways for estradiol oxidation, 2- hydroxylation and 16a-hydroxylation, was postulated to determine a woman's risk of breast cancer, based on the finding that estrogen 16a-hydroxylase activity was increased in women with breast cancer (2) . Over time, the ratio of 2-hydroxyestrone to 16a-hydroxyestrone (the 2/16 ratio) has been emphasized as an indicator of the balance between the two pathways and of reduced breast cancer risk. Estradiol is first reversibly converted to estrone by 17,B oxidation; most of the estrone is then irreversibly oxidized to 2-hydroxyestrone or 16a-hydroxyestrone, the initial metabolites formed along these two pathways. Recently, alteration of the balance between these two metabolic pathways has been proposed as the mechanism by which certain pesticides, herbicides, plastics, and other xenoestrogens (foreign estrogens) may increase the risk of breast cancer (3, 4) and by which a low-fat diet (5) or indoles (6, 7) may decrease the risk.
In vitro studies, using cell cultures and organ explants, and animal studies indicate that 16a-hydroxyestrone is a potent estrogen, genotoxic, and tumorigenic and that 2-hydroxyestrone is a weak estrogen and an estrogen antagonist (8, 9) . Evidence in humans is more limited. Breast tissue from breast cancer patients had nearly 5 times more 166a-hydroxylase activity than comparable tissue from women without cancer (10) . A metabolic study in humans demonstrated that a decrease in dietary fat decreased 16a-hydroxylated estrogens in the urine (5) , although studies of urinary estrogen profiles in vegetarian and omnivorous women and in women with breast cancer indicated the relationships are complex (11) (12) (13) . To our knowledge, the relationships between breast cancer risk and 2-hydroxyestrone and 16a-hydroxyestrone, and the two metabolic pathways they represent, have not yet been examined in a case-control or cohort study, primarily because of the difficulty of assessing the two pathways in humans using radiolabeled tracer or gas chromatography-mass spectroscopy (GCMS) methods.
Recently, rapid and simple enzyme immunoassays (EIAs) were developed to evaluate the balance between these two metabolic pathways, and possibly to serve as a biomarker of breast cancer risk (14) . The EIAs measure 2-hydroxyestrone and 166a-hydroxyestrone in unextracted urine. The initial studies that examined sensitivity, specificity, coefficients of variation, recovery, and validation, relative to a GC-MS method, have been published (14) .
We hope to use these EIAs in a casecontrol study of breast cancer in AsianAmerican women as one of many measures of endogenous hormone levels and hormone metabolism that might explain why breast cancer incidence rates have historically been 4 to 7 times higher in the United States than in Asia (15) . This (14) . For aliquots whose values fell off the standard curve, either twice the volume or a dilution of the urine was assayed. The between-and within-assay coefficients of variation for 2-hydroxyestrone, 16a-hydroxyestrone, and their ratio with this EIA kit have been reported to be consistently less than 9% (14) . In Adlercreutz's laboratory, GC-MS was used to characterize the estrogen profile in urine after hydrolysis of conjugates (16) . Fourteen endogenous estrogensestrone, estradiol, estriol, 2-hydroxyestrone, 2-hydroxyestradiol, 2-methoxyestrone, 2-methoxyestradiol, 4-hydroxyestrone, 1 5a-hydroxyestrone, 16a-hydroxyestrone, 1 (17) . Estrogens with vicinal cis-hydroxyls and diphenolic compounds were fractionated on the borate and bicarbonate forms of QAE-Sephadex, respectively. Neutral steroids were removed by the free base form of DEAE-Sephadex, after which estrogens were separated into two groups using Lipidex 5000 in a straight phase system. Following trimethylsilyl ether derivatization, estrogens were analyzed by capillary gas chromatography with stable isotope dilution mass spectrometry. Deuterated internal standards were available for all the estrogens except 16a-hydroxyestrone and 17-epiestriol, and were used to correct for losses after the initial hydrolysis step. The limit of detection was estimated to be 0.5 to 3 nmol/liter. The coefficients of variation in premenopausal urine samples for the 10 major estrogens, including 2-hydroxyestrone and 16a-hydroxyestrone, have been reported to be 4 to 7% (16, 17) .
Satistical Methods
The means of the triplicate EIA readings for each aliquot were analyzed on the log scale (base 10) to reduce the dependence of the standard deviation of the response on the mean response. The transformation is also appropriate because -studies of cancer Associations were examined using the Spearman rank order correlation and, after log transformation, the Pearson correlation. The Spearman rank order correlation is the usual correlation coefficient for ranked outcomes. metabolites, between-individual variability was highest for the midfollicular premenopausal women and lowest for the postmenopausal women. For women in each menstrual group, between-individual variation appeared greater for 2-hydroxyestrone than 166a-hydroxyestrone. Apart from the unusually low readings for both metabolites for one aliquot at month 3 from a midluteal premenopausal woman, a single EIA measurement, in general, reliably characterized each premenopausal woman. To see this, note that the lines connecting the midpoints of the two readings in each month for each woman are usually clearly separated (Figures 1 and 2) . However, for the postmenopausal women, single EIA readings were not as reliable for characterizing an individual woman; in particular, the midpoint lines cross one another. Among the postmenopausal women, a narrower range in metabolite values and, to a lesser extent, the increased assay variability contributed to the overlapping lines and the less definitive discrimination between women.
For both 2-hydroxyestrone and 16a-hydroxyestrone, the mean of the eight EIA measurements performed on urine from each woman in the spring of 1994 was compared with the single repeat measurement made a year later (Figure 3 ). Readings for both estrogen metabolites increased, with the most striking effect seen in the postmenopausal women. Mean 2-hydroxyestrone readings rose in two of the midfollicular premenopausal women, in five of the midluteal premenopausal women, and in five of the postmenopausal women, while 16o-hydroxyestrone readings rose in two of the midfollicular premenopausal women, in four of the midluteal premenopausal women, and in all five of the postmenopausal women. With few exceptions, rankings among women were maintained. The mean relative increase for each estrogen metabolite was moderate but not statistically significant for the midfollicular premenopausal women, modest for the midluteal premenopausal women, and substantial and statistically significant for the postmenopausal women (Table 1) .
The reproducibility of EIA measurement of 2-hydroxyestrone and 1 6a-hydroxyestrone is summarized and quantified in Table 1 . The coefficient of variation over a 4-month interval, a measure of laboratory variability, was comparable for the two estrogen metabolites and highest in the postmenopausal women (19%), the menstrual group with the lowest concentration of two dominant pathways for estrogen metabolism-2-hydroxylation and 16-hydroxylation ( Figure 5 ). To evaluate this hypothesis, we assumed that 2-hydroxyestrone and 2-methoxyestrone are the major metabolites on the 2-hydroxylation pathway and that 1 6a-hydroxyestrone, 1 7-epiestriol, and estriol are the major metabolites on the 16a-hydroxylation pathway (PK Siiteri, personal communication.) There are differences of opinion among endocrinologists about which estrogen metabolites are the dominant ones, and whether the same pattern is seen in all women. Using the GC-MS results for all 15 women, the ratio of 2-hydroxyestrone to 16a-hydroxyestrone (the 2/16 ratio) was then compared with the ratio of (2-hydroxyestrone + 2-methoxyestrone) to (16a-hydroxyestrone + 17-epiestriol + estriol). The correlation was excellent (Spearman correlation coefficient = 0.90; Pearson correlation coefficient = 0.96) and is shown in the scatter plot in Figure  6A . In addition, the 2/16 ratio seemed consistently predictive; it reflected the relative importance of the competing pathways for the women in each menstrual group. In the late 1970s, Lemon and colleagues (19, 20) hypothesized, on the basis of mammary carcinogenesis studies in rodents, that women with a low ratio of estriol to estrone and estradiol combined would have a high risk of breast cancer. The hypothesis was thought to explain the protective effect of full-term pregnancies (estriol is extremely high relative to the other two estrogens in the second half of pregnancy) and the higher incidence of breast cancer in Western than in Asian countries (21) . However, in several casecontrol studies, urinary levels of these estrogens were determined and the calculated ratio was not convincingly related to breast cancer risk (21, 22 (1) . Thus, we examined the relationship between the 2/16 ratio and total urinary estrogens ( Figure  6C ). The correlation among the 15 women in our study was poor (Spearman correlation coefficient = 0.48; Pearson correlation coefficient = 0.56).
Discussion
To summarize, laboratory reproducibility of the EIAs for 2-hydroxyestrone and 16a-hydroxyestrone was good for both metabolites in premenopausal women (coefficient of variation = 8-14%) and sat (24) . We are now evaluating the reproducibility and validity, relative to GC-MS, of these EIAs.
Certain of our conclusions were based on small numbers; in particular, our assessment of validity was based on a total of 15 women, with 5 in each menstrual group. A larger sample of women would also have strengthened our estimate of between-individual variation in levels of these two estrogen metabolites and its magnitude relative to laboratory variation.
In addition, we had no information on within-individual variation in levels of these metabolites-the degree to which different days of the menstrual cycle, menopausal status, and age may affect estrogen metabolite levels. Within-individual variability, as well as laboratory variability, must be small relative to between-individual variability for an assay to reliably characterize an individual.
Our evaluation of the EIAs for 2-hydroxyestrone and 16a-hydroxyestrone was unusually demanding. Most of the recent published articles on hormone measurement techniques have evaluated only reproducibility, not validity (25) (26) (27) (28) . In addition, measurement by GC-MS may not be absolutely correct. We did not test the reproducibility of the GC-MS technique. Adlercreutz et al. (11) estimated that probably 5%, and possibly as much as 10%, of the hormone metabolites might have been lost in the GC-MS analysis because of incomplete hydrolysis prior to the introduction of deuterated internal standards.
In evaluating the validity of these EIAs, our focus was on biochemical validity, based on the published specificities of the two monoclonal antibodies. However, our ultimate interest is in biologic validitythe ability of this EIA kit, and any subsequent modifications of this kit, to predict risk of breast cancer in individual women. Even if the two antibodies are not totally specific for 2-hydroxyestrone and 16ax-hydroxyestrone and cross-react with other 2-substituted and 16a-substituted estrogen metabolites, respectively, the EIAs may still provide meaningful measures of the competition between these two metabolic pathways. Thus, we plan to evaluate these ELAs in a case-control study of breast cancer. By focusing attention on patterns of hormone metabolism, not just absolute hormone levels, this kit suggests new approaches for studies of endogenous hormones and breast cancer.
